workforce news from FierceBiotech
News
Gilead doubles jobs, space to boost development
While many biotech and pharma companies are planning layoffs and restructuring to reduce costs, Gilead Sciences plans to double its campus at its Foster City headquarters--swelling from 629,154... Read more...
Jazz Pharma axes staffers after delaying two trials
Jazz Pharmaceuticals says it needs to extend the development time line for two key drug programs, a move that triggered a decision to lay off 33 workers, or eight percent of its workforce. In a... Read more...
ImaRx to cut staff
ImaRx says it will immediately cut its workforce after scrapping a planned deal to sell its urokinase inventory and related assets to Microbix Biosystems for $17 million. Read more...
MedImmune to hire 800 in pipeline push
With plans to double the number of experimental therapies in its pipeline by 2010, MedImmune is laying plans to hire 800 new staffers by the end of this year, according to a report in the Washington... Read more...
SPOTLIGHT: Sunesis cuts 60 jobs
Sunesis Pharmaceuticals is realigning to focus on the development voreloxin (SNS-595), its lead drug candidate. The company is expanding activities around late-stage development of the drug and... Read more...
Pharmacopeia cuts 15% of workforce
In an effort to streamline its business and save cash, Pharmacopeia is laying off 15 percent of its workforce and decreasing "other expenses through improved operational efficiencies and increased... Read more...
FDA blisters Purdue for 'poor' OxyContin data
Researchers for Purdue Pharma laid out their data for a new, tamper-resistant form of the blockbuster... Read more...
Purdue jumps ahead in pain drug race
With three significant development programs at work on a tamper-free alternative to the blockbuster OxyContin franchise, Purdue Pharma is bracing for an upcoming FDA panel review of its new pain... Read more...
SPOTLIGHT: Genta restructures
restructuresWith the FDA unwilling to budge on its decision to demand more data before it approves... Read more...
Arizona gets its own early-stage venture fund
The Translational Accelerator has opened its doors to all biotech companies in Arizona--or any life sciences company thinking about moving there. And it has $20 million in venture funds to welcome... Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
